Advancing natural killer therapies against cancer

Emilie Narni-Mancinelli; Eric Vivier

doi:10.1016/j.cell.2022.04.006

Advancing natural killer therapies against cancer

Cell. 2022 Apr 28;185(9):1451-1454. doi: 10.1016/j.cell.2022.04.006.

Authors

Emilie Narni-Mancinelli¹, Eric Vivier²

Affiliations

¹ Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France. Electronic address: narni@ciml.univ-mrs.fr.
² Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France; Innate Pharma Research Laboratories, Innate Pharma, Marseille, France; APHM, Hôpital de la Timone, Marseille-Immunopôle, Marseille, France.

PMID: 35487189
DOI: 10.1016/j.cell.2022.04.006

Abstract

Natural killer (NK)-based therapies against cancer are emerging, but the understanding of NK cell functions needs to be completed to optimize these treatments. In this issue, Pan et al. (2022) show that pro-apoptotic molecules, such as BH3-mimetics, synergize with NK cells to induce mitochondria-driven apoptosis in tumor cells, thereby enhancing the efficacy of NK cell therapies.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Apoptosis
Humans
Immunotherapy, Adoptive
Killer Cells, Natural*
Mitochondria / pathology
Neoplasms* / pathology
Neoplasms* / therapy